



## Original Article



## The Effectiveness of Azithromycin versus Cefixime in the Treatment of Typhoid Fever in Children

Rafique Ahmed Ujjan<sup>1</sup>, Ghulam Serwar Shaikh<sup>2</sup>, Soobia Pathan<sup>3</sup>, Madiha Niamat<sup>3</sup>, Faiza Shaikh<sup>4</sup> and Kashif Ali<sup>5</sup>

<sup>1</sup>Department of Pediatric, Khairpur Medical College, Teaching Hospital Khairpur Mirs, Khairpur, Pakistan

<sup>2</sup>Department of Biochemistry, Shaheed Mohtrama Benazir Bhutto Medical University, Larkana, Pakistan

<sup>3</sup>Department of Pharmacology, Liaquat University of Medical and Health Sciences, Jamshoro Pakistan

<sup>4</sup>Department of Physiology, Karachi Institute of Medical Sciences Malir Cantt, Karachi, Pakistan

<sup>5</sup>Department of Medicine, Bilawal Medical College, Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan

## ARTICLE INFO

**Keywords:**

Azithromycin, Cefixime, Efficacy, Typhoid Fever

**How to Cite:**

Ujjan, R. A., Shaikh, G. S., Pathan, S., Niamat, M., Shaikh, F., & Ali, K. (2024). The Effectiveness of Azithromycin versus Cefixime in the Treatment of Typhoid Fever in Children: Azithromycin versus Cefixime in the Treatment of Typhoid Fever. *Pakistan Journal of Health Sciences*, 5(10). <https://doi.org/10.54393/pjhs.v5i10.2105>

**\*Corresponding Author:**

Rafique Ahmed Ujjan  
Department of Pediatric, Khairpur Medical College,  
Teaching Hospital Khairpur Mirs, Khairpur, Pakistan  
[ahmedrafique267@gmail.com](mailto:ahmedrafique267@gmail.com)

Received Date: 18<sup>th</sup> August, 2024

Acceptance Date: 26<sup>th</sup> October, 2024

Published Date: 31<sup>st</sup> October, 2024

## ABSTRACT

Typhoid fever is brought on by the Salmonella Typhibacteria. Typhoid fever can present with a wide range of clinical symptoms, making diagnosis difficult. Salmonella Typhi is a bacterium that spreads quickly in unsanitary environments. In addition, this disease is more prevalent in places with inadequate hygienic conditions, economically unsustainable poor people, and rural areas with a lack of safe drinking water supply are at high risk of developing typhoid fever. **Objective:** To compare the results of azithromycin versus cefixime in the treatment of typhoid fever in children. **Methods:** A clinical/Quasi-Experimental study was conducted in the pediatric ward, Liaquat University Hospital Jamshoro/Hyderabad by convenience sampling technique within the time frame of six months. SPSS Version 26.0 was employed to analyze the data, by using chi square test. **Results:** Out of 270 subjects, Individuals of age group (2-5 years) were more affected (53.4%). The male population was more affected (57.8%). Signs and symptoms like fever, abdominal pain, diarrhea and constipation were observed and calculated in this study. Clinical cure occurred in 110 (81.4%) of 135 patients treated with azithromycin, compared with 68 (50.3%) of 135 patients treated with cefixime ( $p$ -value= $<0.001$ ). **Conclusions:** It was concluded that everyday taking of oral azithromycin may present a plain cure for typhoid fever brought on by drug-resistant or susceptible strains of Salmonella Typhi, which makes it potentially useful in places with limited access to healthcare services. Most of the children aged between 2 to 5 years with male predominance were affected.

## INTRODUCTION

The major health threat is typhoid fever, especially for children [1]. Salmonella Typhibacteria, which causes typhoid, spreads quickly in unsanitary environments [2]. The prevalence of this disease is highest in places with inadequate sanitation. Typhoid Fever is a significant cause of global mortality and morbidity, yet it has a high incidence in developing countries. According to estimates, there are 11-21 million cases of typhoid fever worldwide each year, with 1,20,000-1,60,000 deaths [3, 4]. Before, there were about 6,00,000 deaths and 16 million cases, but the fatality rate had dropped. Ninety-three percent of cases worldwide are reported prevalence of typhoid fever in various socio-demographic groups in southeast Asia [5]. Pakistan is a developing country with a high rate of typhoid disease.

Pupils older than five years have the majority of difficulties, with only one-third of patients experiencing intestinal fever. Overcrowding, bad laundry, and low personal well-being, goods, the use of water without heating, meat sharing, beverages of ice cream, lower socioeconomic class, poor sanitation in homes are all elements that present to the development of typhoid and paratyphoid fever [6-8]. It affects approximately 21 million people worldwide each year, with the majority of cases occurring in South Asia. According to the World Health Organization (WHO), there have been between 11 and 21 million cases of typhoid fever globally, with a resulting mortality toll of between 1,20,000 and 1,60,000 [9-11]. The health authorities in Pakistan have confirmed that between



2016 and 2020, there were approximately 22,354 cases of typhoid fever, and 15,717 cases were widespread drug-resistant cases that came from diverse parts of Sindh [12-15]. Typhoid fever is often spread by contaminated water, during the summer season and the rainy season. A derivative of the fundamental macrolide, azithromycin exhibits superior anti-gram-negative bacterial action compared to erythromycin. Cefixime is a third-generation oral cephalosporin using a spectrum related to other third-generation cephalosporin [16-17].

This study aims to analyze the efficacy of azithromycin, a new macrolide, compared to that of cefixime, as a first-line drug for the therapy of uncomplicated typhoid fever in children.

## METHODS

A clinical Quasi-Experimental study was conducted in the pediatric ward, Liaquat University Hospital Jamshoro Hyderabad by a non-probability consecutive sampling technique contained by a year i.e., from 1st January 2019 to 31 December 2019 after approval by the Ethical Committee of LUMHS Jamshoro, LUMHS/REC/-752. Informed consent was taken by patients/guardians. Detailed medical history was taken followed by a thorough clinical examination of patients presented with clinical susceptibility to typhoid fever. All diagnosed patients of typhoid fever, either gender, age range from 2-12 years were included and patients with allergy to cefixime or macrolides, for most complications of typhoid fever-like intestinal perforation, septicemia, dysphagia, oral medications and substantial disease underneath, requiring chronic medication and immune-deficiencies were excluded from the study. A sample size of 270 patients (135 in each group) was calculated with an 80% confidence level, 4.66% absolute precision and by taking an expected percentage of the cure rate of Azithromycin and cefixime as 87% (0.87) and 93% (0.93) for treating typhoid fever among children [13]. Diagnosed cases of typhoid fever based on blood culture (before treatment) were enrolled in the study and they were equally divided into two groups (Group-I 135 azithromycin recipients and Group-II 135 cefixime recipients). All patients were admitted through the Outpatient Department (OPD) or Emergency Room (ER) in the pediatric ward. Reports on patient demographics, present complaints, symptoms, and temperature were recorded. Detailed history, blood count and differential count were sent at baseline for a blood sample, and the study group was randomly divided into two groupings, Azithromycin recipients received orally 100mg/kg/day, OD, and cefixime 10 mg/kg/12 hourly. Every day, each patient will be evaluated and proforma updated in terms of appetite, hepatomegaly, splenomegaly, constipation/diarrhea, headache, and abdominal pain.

Blood culture was performed on day one and day ten for correlation to treatment effectiveness. SPSS version 26.0 was used for the data analysis. Quantitative data were presented with mean  $\pm$  SD and qualitative data with frequency and percentage. Comparison of qualitative variables between groups was done with the Chi-Square test and the comparison of quantitative variables between groups was done with the help of the Independent sample t-test. p-value <0.05 was considered statistically significant.

## RESULTS

Of the total sample, 144 (53.3%) of the sample was aged between 2 to 5 years, 81 (30%) patients were seen in the age group 6 to 9 years and 45 (16.6%) observed in the age group 10 to 12 years with the mean age. Gender distribution shows a male predominance in both groups 156 (57.8%) were male and 114 (42.2%) were female (Table 1).

**Table 1:** Demographic Characteristics of Participants

Age (Years)	Group I	Group II
2-5	60 (44.44%)	84 (62.22%)
6-9	47 (34.82%)	34 (25.19%)
10-12	28 (20.74%)	17 (12.59%)
<b>Mean <math>\pm</math>SD</b>	8.16 $\pm$ 7.815	7.60 $\pm$ 8.518
<b>Gender</b>	<b>Male</b>	<b>Female</b>
Group I	86 (63.70)	49 (36.30)
Group II	70 (51.86)	65 (48.14)

Signs and symptoms observed on admissions of patients between groups. On admission, signs and symptoms were seen among all the patients. The mean  $\pm$  SD of haemoglobin count was noted in Group I (9.200  $\pm$  1.4300) and Group II was (9.457  $\pm$  1.4712) and the Mean  $\pm$  SD of total leukocyte was noted in Group I (31.466  $\pm$  156.4817) and Group II was (17.669  $\pm$  2.2507). Out of 270 patients, fever was present in 266 (98.5%) patients and abdominal pain was seen in 252 patients (93.3%), 83 (30.7%) patients had constipation, diarrhea was present in 177 (65.6%) and the headache was present in 144 patients (53.3%) (Table 2).

**Table 2:** Signs and Symptoms Observed on Admissions of Patients Between Groups

Variable	Group I	Group II	p-Value
<b>Haemoglobin</b>	9.200 $\pm$ 1.4300	9.457 $\pm$ 1.4712	0.147
<b>Total Leucocyte Count</b>	31.466 $\pm$ 156.4817	17.669 $\pm$ 2.2507	0.307
<b>Fever</b>			
Yes	134 (99.3%)	132 (97.8%)	0.62
No	1 (0.7%)	3 (2.2%)	
<b>Abdominal Pain</b>			
Yes	128 (94.8%)	124 (91.9%)	0.46
No	7 (5.2%)	11 (8.1%)	
<b>Constipation</b>			
Yes	33 (24.4)	50 (37%)	0.03
No	102 (75.6%)	85 (63%)	

Diarrhea			
Yes	89 (65.9%)	88 (65.19)	0.59
No	46 (34.1)	47 (34.81)	
Headache			
Yes	84 (62.2%)	60 (44.4%)	0.005
No	51 (37.8%)	75 (55.6%)	

Microbial elimination occurred significantly in 110(81.4%) of 135 patients cured with azithromycin versus 68(50.3%) of 135 patients treated with cefixime ( $p$ -value=0.005). The patient with microbiological failure in the azithromycin group had *Salmonella Typhi* isolated from blood on both day 05 and day 10, whereas the patient with microbiological failure in the cefixime group had *Salmonella Typhi* isolated from blood on day 10 (table 3).

**Table 3:** Patients' Distribution According to Blood Culture after Therapy

Blood culture after therapy	Azithromycin	Cefixime	Total	p-value
Positive	25 (18.6%)	67(49.7%)	92 (34.0%)	0.001
Negative	110 (81.4%)	68 (50.3%)	178 (66.0%)	

The distribution of patients according to efficacy between groups was done. Clinical cure occurred in 110(81.4%) of 135 patients treated with azithromycin, compared with 68(50.3%) of 135 patients treated with cefixime ( $p$ -value=0.005). Of these, 25 patients with clinical failure in the azithromycin group, 67 had failed in the cefixime group as a result of the slow declaration of fever (Table 4).

**Table 4:** Distribution of Patients According to Efficacy between Groups

Efficacy	Group I	Group II	p-value
Yes	110 (81.4%)	68 (50.3%)	0.005
No	25 (18.6%)	67 (49.7%)	

## DISCUSSION

Malaise, fever, pain and discomfort of the abdomen, rose-colored eruptions, splenomegaly, occasionally hepatomegaly, constipation, diarrhea, toxemia, and leukopenia are the main symptoms of typhoid fever. Large-scale occurrences of typhoid disease persist in nations with inadequate sanitation. Since typhoid fever causes a high rate of morbidity and mortality, it has been identified as the most contagious disease in South Asian nations like Pakistan [15]. Several cases are recorded nationwide each year. It predominates in places with a dearth of sanitary food and safe drinking water. Like other Asian nations, typhoid fever is influenced by various socioeconomic factors [16-17]. In Pakistan, typhoid fever is a very common sickness. Third-generation cephalosporin is becoming the drug of choice more often due to multidrug-resistant (MDR) strains in these regions; however, these drug classes have poor cellular penetrance, which results in poor overall clinical outcomes indicators such as prolonged fever

clearance time. Alternative medication regimens are also recommended, such as azithromycin monotherapy [18]. According to this study, children with simple typhoid fever can benefit from a 6-day azithromycin therapy. These patients' clinical and microbiological cure rates were close to 80% [19, 20]. The most frequently reported symptoms among the patients in this study were fever (98.5%), followed by diarrhea (65.5%) and abdominal discomfort (93.3%). Our findings concurred with those of Gamal et al., [21]. It has been demonstrated that typhoid is prevalent in Southeast Asian newborns and young children. The majority of research categorized by gender revealed that typhoid affects men more frequently than women. For example, males were more affected than females in an Iraqi study by Medhat and Aljanabay [22]. Male may be more likely to be affected than females since they spend more time outside the home than females, among other possible explanations. The developing children's underdeveloped immune systems are one of the causes of ages 1 to 10 being susceptible, immature immune system in growing children makes them exposed to this enteric pathogen [10]. In this study, Azithromycin was used on a low dose of 6 days once a day and was compared with cefixime. One reason is for this to be reduced in azithromycin-related side effects and this low dose in typhoid fever has already been demonstrated to be effective in studies that have not made a comparison. The positive outcome of this study led us to test if a shorter course of treatment in children could also be used. The current trials end the message that oral azithromycin with a dose of 10 mg/kg/ day, OD, is better for clinical cures for 6 days compared with 100 mg/kg/day in intravenous ceftriaxone at 2 doses divided over seven days. In children with an efficacy rate of more than 95%, azithromycin is apparently an effective drug for treating straightforward typhoid fever. In previous studies with azithromycin treatment, failure rates of 9.3% were observed [11]. A compared, randomized trial conducted by Giri et al., [23] shown that azithromycin is a very successful treatment for children with uncomplicated typhoid fever. Results of the current study showed that participants taking either azithromycin had clinical and microbiological cure rates of 80%, which compares favourable to results from previous trials using conventional antibiotics to treat typhoid fever. Compared to the third-generation cephalosporin, azithromycin is significantly less expensive and appears to be a good substitute. Convenient once-daily azithromycin dosage combined with a brief treatment duration might increase patient compliance. Therefore, the biggest benefit would still be how simple it is to treat typhoid fever.

## CONCLUSIONS

It was concluded that in children, oral azithromycin (10mg/kg/day for 6 days) is more effective than cefixime (20mg/kg/day for 10 days) for the therapy of typhoid fever. Clinical cure occurred 81% of the patients treated with azithromycin, compared with 50% of the patients treated

with cefixime. Every day taking of oral azithromycin may present a plain cure for typhoid fever brought on by drug-resistant or susceptible strains of *Salmonella Typhi*, which makes it potentially useful in places with limited access to healthcare services. Most of the children aged between 2 to 5 years with male predominance were affected.

### Authors Contribution

Conceptualization: RAU, KA

Methodology: RAU, GSS

Formal analysis: RAU

Writing review and editing: SP, MN

All authors have read and agreed to the published version of the manuscript.

### Conflicts of Interest

All the authors declare no conflict of interest.

### Source of Funding

The author received no financial support for the research, authorship and/or publication of this article.

### REFERENCES

- [1] Makkar A, Gupta S, Khan ID, Gupta RM, Rajmohan KS, Chopra H et al. Epidemiological Profile and Antimicrobial Resistance Pattern of Enteric Fever in a Tertiary Care Hospital of North India—a Seven Year Ambispective Study. *Acta Medica*.2019 Jan;61(4):125-30. doi:10.14712/18059694.2018.130.
- [2] Ayub U, Khattak AA, Saleem A, Javed F, Siddiqui N, Hussain N et al. Incidence of Typhoid Fever in Islamabad, Pakistan. *American-Eurasian Journal of Toxicological Sciences*.2015;7(4):220-3. doi: 10.5829/idosi.ajejts.2015.7.4.95188.
- [3] Ahmad M, Saeed M, Rasheed F, Rasool MH, Jamil I, Saba N et al. Typhoid Fever: Pakistan's Unique Challenges and Pragmatic Solutions. *Journal of Islamabad Medical & Dental College*.2024 Apr;13(1):15 1-61. doi: 10.35787/jimdc.v13i1.1179.
- [4] Frenck Jr RW, Mansour A, Nakhla I, Sultan Y, Putnam S, Wierzba T, Morsy M, Knirsch C. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. *Clinical infectious diseases*. 2004 Apr 1;38(7):951-7.
- [5] Nair B, Simalti A, Sharma S. Study comparing ceftriaxone with azithromycin for the treatment of uncomplicated typhoid fever in children of India. *Annals of Tropical Medicine and Public Health*. 2017;10(1).
- [6] Hidayatallah Z. Comparative Analysis of Azithromycin And Cefixime In The Treatment of Typhoid Fever. *Journal of Advanced Zoology*. 2024 Jan 3;45: 48. Baloch F, Abbasi HA, Shaikh MM, Sagar P, Memon A,
- [7] Amir M. Drug Resistant XDR Typhoid in Children Admitted in a Tertiary Care Hospital. *Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University*.2024 Mar;20(1):69-73. doi: 10.48036/apims.v20i1.964.
- [8] Imran H, Saleem F, Gull S, Khan Z. Uncovering the Growing Burden of Enteric Fever: A Molecular Analysis of *Salmonella Typhi* Antimicrobial Resistance. *Microbial Pathogenesis*.2024 Jun;191: 10 6676. doi: 10.1016/j.micpath.2024.106676.
- [9] Browne AJ, Chipeta MG, Fell FJ, Haines-Woodhouse G, Hamadani BH, Kumaran EA et al. Estimating the Subnational Prevalence of Antimicrobial Resistant *Salmonella Enterica* Serovars Typhi and Paratyphi A Infections in 75 Endemic Countries, 1990–2019: A Modelling Study. *The Lancet Global Health*.2024 Mar; 12(3):e406-18.
- [10] Khan A, Khan I, Babar AN, Khan Y, Shah G, Khan MI. Effectiveness of Oral Azithromycin in Treating Enteric Fever: A Hospital-Based Study on Pediatric Patients. *Cureus*. 2024 Aug 16;16(8):e67024.
- [11] Yasmeen O, Murad T, Sultana A, Khan Z, Nahar S. Typhoid Fever: Azithromycin vs. Ceftriaxone for the Treatment of Mild to Moderate Cases in Children. *Asian Journal of Medicine and Health*.2023 May 18;21(8):62-9.
- [12] Uzzell CB, Abraham D, Rigby J, Troman CM, Nair S, Elviss Net al. Environmental Surveillance for *Salmonella Typhi* and Its Association with Typhoid Fever Incidence in India and Malawi. *The Journal of Infectious Diseases*.2024 Apr;229(4):979-87. doi: 10.1093/infdis/jiad427.
- [13] Begum B, Haque MA, Ahmed MS, Islam MN, Ahsan MM, Khan AH et al. Comparison Between Azithromycin and Cefixime in the Treatment of Typhoid Fever in Children. *Mymensingh Medical Journal*. 2014 Jul;23(3) :441-8.
- [14] Carey ME, Dyson ZA, Ingle DJ, Amir A, Aworh MK, Chattaway MA et al. Global Diversity and Antimicrobial Resistance of Typhoid Fever Pathogens: Insights from A Meta-Analysis of 13,000 *Salmonella Typhi* Genomes. *Elife*.2023 Sep;12:e8586 7.
- [15] Nirmal K, Saini V, Ahmad N, Singh NP. Assessment of Blood Culture and Tube Agglutination Serology Test for the Diagnosis of Typhoid Fever Amongst Malaria-Negative Patients: A One-Year Hospital-Based Study. *Healthcare in Low-resource Settings*. 2023 Jun;11(1). doi: 10.4081/hls.2023.11345.
- [16] Jadav PK, Sukharamwala PH, Mehta NT. Drug Utilization Study in Pediatric Patients with Typhoid Fever. *Journal for Research in Applied Sciences and Biotechnology*. 2023 May 15;2(2):241-7.
- [17] Frenck Jr RW, Nakhla I, Sultan Y, Bassily SB, Girgis YF, David J et al. Azithromycin Versus Ceftriaxone for the Treatment of Uncomplicated Typhoid Fever in Children. *Clinical Infectious Diseases*.2000 Nov;31(5) :1134-8. doi: 10.1086/317450.



- [18] Mehreen B, Jehanzeb S, Khan HU, Shaheen R, Iqbal S, Khan S. Comparison of Efficacy of Azithromycin Versus Ceftriaxone in Treatment of Enteric Fever. *Pakistan Journal of Medical & Health Sciences*. 2023 Apr 29;17(03):432-.
- [19] Machakanur V. A Clinical Trial of Treatment of Uncomplicated Typhoid Fever: Efficacy of Azithromycin Versus Ceftriaxone. Doctoral dissertation, Rajiv Gandhi University of Health Sciences(India). 2014.
- [20] Baig U, Mehdi SM, Iftikhar N. A pattern of antibiotic drug resistance of Salmonella Typhi and Salmonella Paratyphi among children with enteric fever in a tertiary care hospital in Lahore, Pakistan. *Croatian Medical Journal*. 2023 Aug;64(4):256.
- [21] Machakanur V, Rohit S. AZITHROMYCIN VERSUS CEFTRIAXONE – WHICH IS BETTER IN UNCOMPLICATED TYPHOID FEVER? A CLINICAL TRIAL IN A TERTIARY CARE HOSPITAL. *Journal of Evolution of Medical and Dental Sciences*. 2019 Apr 29;8(17):1394-9.
- [22] Islam DR, Shumi DM, Parvin DS, Rejwana DI, Nur DF, Haque DM. The outcome of azithromycin and ciprofloxacin for treatment of uncomplicated typhoid fever. *Sch J Appl Med Sci*. 2023 Mar;3:662-7.
- [23] Giri A, Karkey A, Dongol S, Arjyal A, Maharjan A, Veeraraghavan B et al. Azithromycin and Cefixime Combination Versus Azithromycin Alone for the Out-Patient Treatment Of Clinically Suspected or Confirmed Uncomplicated Typhoid Fever in South Asia: A Randomised Controlled Trial Protocol. *Wellcome Open Research*. 2021 Nov;6: 207. doi: 10.12688/wellcomeopenres.16801.1.